HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion.

AbstractOBJECTIVE:
Atracurium is sometimes used for muscle relaxation in patients undergoing mechanical ventilation. Use of atracurium in high doses or for a long period of time has raised the possibility of the accumulation of laudanosine, a breakdown product known to cause seizure activity in animals. The objective of this report was to see if laudanosine accumulation and seizure activity had occurred in a patient who had received a long-term, relatively high-dose infusion of atracurium.
DESIGN:
Case report. The patient received atracurium for 38 days, at rates ranging from 0.3 to 0.96 mg/kg/hr. An electroencephalogram (EEG) was done before the discontinuation of the infusion, and plasma concentrations of atracurium and laudanosine were measured at, and after, the termination of the atracurium infusion. The laudanosine elimination half-life was calculated.
SETTING:
Intensive care unit.
PATIENT:
A 23-yr-old woman admitted with sickle cell crisis, complicated by acute chest syndrome, acute respiratory distress syndrome, and hepatic and renal failure.
INTERVENTIONS:
None.
MEASUREMENTS AND MAIN RESULTS:
As expected, laudanosine concentrations were increased but were below the level reported to cause seizure activity in animals. Laudanosine elimination half-life was prolonged to 617 mins, which was consistent with previously reported values. The patient's EEG was normal, with no ictal pattern.
CONCLUSIONS:
Despite long-term use of high doses of atracurium infusion and the increased elimination half-life of laudanosine, only moderate accumulation of laudanosine occurred, and the EEG was normal. Hence, it appears unlikely that toxic concentrations of laudanosine would be reached, even in a critically ill patient.
AuthorsA M Grigore, L Brusco Jr, M Kuroda, R Koorn
JournalCritical care medicine (Crit Care Med) Vol. 26 Issue 1 Pg. 180-3 (Jan 1998) ISSN: 0090-3493 [Print] United States
PMID9428564 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Isoquinolines
  • Neuromuscular Nondepolarizing Agents
  • Atracurium
  • laudanosine
Topics
  • Adult
  • Atracurium (adverse effects, pharmacokinetics)
  • Electroencephalography
  • Female
  • Follow-Up Studies
  • Half-Life
  • Hemoglobin SC Disease (complications, metabolism)
  • Humans
  • Infusions, Intravenous
  • Isoquinolines (adverse effects, pharmacokinetics)
  • Multiple Organ Failure (complications, metabolism)
  • Neuromuscular Nondepolarizing Agents (adverse effects, pharmacokinetics)
  • Respiratory Distress Syndrome (complications, metabolism)
  • Seizures (chemically induced, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: